
Slingshot Therapeutics appoints Ed Savory as head of chemistry
Ella Day | May 21, 2025 | Appointment | Research and Development | Corporate, Pharmacy, Slingshot Therapeutics, appointment
Slingshot Therapeutics has announced the appointment of Ed Savory as head of chemistry. He will oversee the company’s chemistry strategy and operations, working with academic partners and contract research organisations to advance its small molecule pipeline towards clinical development.
Savory brings over 22 years of experience in drug discovery, having held senior roles across venture-capital backed start-ups and biotech companies in the UK, US and Europe. Prior to joining Slingshot, he was senior vice president of drug discovery at Benevolent AI, where he led multidisciplinary teams developing candidate drugs using artificial intelligence-driven approaches.
He has also held scientific leadership positions at Proximagen (Upsher-Smith) and Cambridge Biotechnology (Biovitrum).
Richard Wooster, chief scientific officer and director at Slingshot, said: “We’re delighted to welcome Ed to the team. His breadth of experience in drug discovery will be invaluable as we work to translate academic science into clinically meaningful therapies.”
Commenting on his appointment, Savory said: “I’m excited to join Slingshot at this pivotal stage of growth. I look forward to working with academic collaborators to accelerate therapeutic programmes and expand the pipeline.”
Slingshot is part of the Syncona Accelerator, focused on advancing academic research into biotech-ready assets in areas of unmet medical need.
Ella Day
21/5/25
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






